MANNKIND CORP Debt Securities, Available-for-sale, Gain (Loss)
MANNKIND CORP (MNKD) reported Debt Securities, Available-for-sale, Gain (Loss) of -$6.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleGainLoss · last filed 2026-02-26
- MANNKIND CORP debt securities, available-for-sale, gain (loss) for the quarter ending 2025-12-31 was $0.00.
- MANNKIND CORP debt securities, available-for-sale, gain (loss) for the quarter ending 2024-12-31 was $0.00.
- MANNKIND CORP debt securities, available-for-sale, gain (loss) for the quarter ending 2024-09-30 was $0.00.
- MANNKIND CORP debt securities, available-for-sale, gain (loss) for the quarter ending 2024-06-30 was -$1.55M, a 266.31% decline year-over-year.
- MANNKIND CORP debt securities, available-for-sale, gain (loss) for fiscal 2025 was -$6.41M.
- MANNKIND CORP debt securities, available-for-sale, gain (loss) for fiscal 2024 was -$1.55M.
- MANNKIND CORP debt securities, available-for-sale, gain (loss) for fiscal 2023 was -$170.00K.
- MANNKIND CORP debt securities, available-for-sale, gain (loss) for fiscal 2022 was -$932.00K.
| Period end | Debt Securities, Available-for-sale, Gain (Loss) 3 month | Debt Securities, Available-for-sale, Gain (Loss) 6 month | Debt Securities, Available-for-sale, Gain (Loss) 9 month | Debt Securities, Available-for-sale, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$6.41M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | -$6.41M 10-Q · filed 2025-11-05 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$1.55M derived: sum of 3 quarters · filed 2026-02-26 | -$1.55M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.55M derived: sum of 2 quarters · filed 2025-11-05 | -$1.55M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$1.55M 10-Q · filed 2025-08-06 | -$1.55M 10-Q · filed 2025-08-06 | ||
| 2023-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.10M derived: sum of 2 quarters · filed 2026-02-26 | -$170.00K derived: sum of 3 quarters · filed 2026-02-26 | -$170.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $932.00K derived: sum of 2 quarters · filed 2024-11-07 | $932.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $932.00K 10-Q · filed 2024-08-07 | $932.00K 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | -$932.00K 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |